Namoxyrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341513

CAS#: 1234-71-5

Description: Namoxyrate is a biochemical.

Chemical Structure

img
Namoxyrate
CAS# 1234-71-5
Instruction

Theoretical Analysis

MedKoo Cat#: 341513
Name: Namoxyrate
CAS#: 1234-71-5
Chemical Formula: C20H27NO3
Exact Mass: 329.20
Molecular Weight: 329.440
Elemental Analysis: C, 72.92; H, 8.26; N, 4.25; O, 14.57

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Namoxyrate; W 1760A; W-1760A; W1760A; W 1769A; W-1769A; W1769A.

IUPAC/Chemical Name: (1,1'-Biphenyl)-4-acetic acid, alpha-ethyl-, compd. with 2-(dimethylamino)ethanol (1:1)

InChi Key: SNUBSRMFCPAKSI-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H16O2.C4H11NO/c1-2-15(16(17)18)14-10-8-13(9-11-14)12-6-4-3-5-7-12;1-5(2)3-4-6/h3-11,15H,2H2,1H3,(H,17,18);6H,3-4H2,1-2H3

SMILES Code: O=C(O)C(CC)C1=CC=C(C2=CC=CC=C2)C=C1.CN(CCO)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 329.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Costa A, Nájera C, Sansano JM. Synthetic applications of o- and p-halobenzyl sulfones as zwitterionic synthons: preparation of ortho-substituted cinnamates and biarylacetic acids. J Org Chem. 2002 Jul 26;67(15):5216-25. PubMed PMID: 12126409.

2: Emele JF, Shanaman JE. Analgesic acitivity of namoxyrate (2-[4-biphenylyl] butyric acid 2-dimethylaminoethanol salt). Arch Int Pharmacodyn Ther. 1967 Nov;170(1):99-107. PubMed PMID: 6056595.

3: Dicarlo FJ, Coutinho CB, Haynes LJ, Sklow NJ. Metabolism of namoxyrate by the rat. Arch Int Pharmacodyn Ther. 1967 May;167(1):206-16. PubMed PMID: 6035098.

4: Cohen A, Corgill DA, Abruzzi W, Ligon CW, DeFelice EA. Double-blind comparison of namoxyrate and d-propoxyphene: a cooperative clinical trial. J New Drugs. 1966 Jan-Feb;6(1):38-44. PubMed PMID: 5330694.

5: Cohen A, DeFelice EA, Beber CR, Shaffer JW, Forbes JA. Evaluation of namoxyrate in the treatment of geriatric arthritics. Curr Ther Res Clin Exp. 1965 Dec;7(12):759-68. PubMed PMID: 4954446.

6: Denko CW, DeFelice EA, Shaffer J. Namoxyrate in rheumatic disorders. Curr Ther Res Clin Exp. 1965 Dec;7(12):749-58. PubMed PMID: 4954445.

7: Bergen JR, Resnick O, DeFelice EA, Freeman H. Characteristics of the circulatory transport of C-14-labeled namoxyrate. Curr Ther Res Clin Exp. 1965 Dec;7(12):741-8. PubMed PMID: 4954444.

8: Rider JA, DeFelice EA, Puletti EJ, Moeller HC. Double-blind comparison of effects of aspirin and namoxyrate on pH of gastric secretions, fecal blood loss, serum iron, and iron-binding capacity in normal volunteers. Curr Ther Res Clin Exp. 1965 Oct;7(10):633-8. PubMed PMID: 4954889.

9: RESNICK O, DEFELICE EA, BERGEN JR, FREEMAN H. THE METABOLISM OF NAMOXYRATE CONTAINING ISOTOPIC CARBON IN MAN. Curr Ther Res Clin Exp. 1965 Aug;7:443-50. PubMed PMID: 14331672.

10: CORGILL DA, LIGON CW, DEFELICE EA. DOUBLE-BLIND COMPARISON OF NAMOXYRATE, CODEINE, ASPIRIN, AND PLACEBO. Curr Ther Res Clin Exp. 1965 May;7:263-74. PubMed PMID: 14286205.

11: Cohen A, DeFelice EA. Double-blind evaluation of namoxyrate, codeine, aspirin, and placebo. J New Drugs. 1965 May-Jun;5(3):53-61. PubMed PMID: 5318983.